Literature DB >> 1580675

Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease.

E Dagli1, J A Warner, C R Besley, J O Warner.   

Abstract

Soluble interleukin-2 receptor (sIL-2R-CD25) concentrations were measured in the sera of 115 children with cystic fibrosis and 45 aged matched controls. Above the age of 4 years children with cystic fibrosis had significantly raised concentrations irrespective of disease status as judged by Shwachman score, lung function, or evidence of pseudomonas colonisation. It is believed that these data indicate that T lymphocyte activation can be detected before there is clinical evidence of lung inflammation due to infection in cystic fibrosis. They support the notion that early use of anti-inflammatory (immunosuppressive) drugs may have a role in delaying the progress of lung damage in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1580675      PMCID: PMC1793340          DOI: 10.1136/adc.67.4.479

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

Review 2.  Human interleukin 2: molecular biology, physiology and clinical possibilities.

Authors:  R Mertelsmann; K Welte
Journal:  Immunobiology       Date:  1986-09       Impact factor: 3.144

3.  Demonstration of two distinct forms of released low affinity-type rat IL-2 receptors.

Authors:  T Herrmann; O Josimovic-Alasevic; A Mouzaki; T Diamantstein
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

Review 4.  The interleukin 2 receptor.

Authors:  K A Smith
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

5.  Immunological studies in cystic fibrosis.

Authors:  M W Turner; J O Warner; C R Stokes
Journal:  Arch Dis Child       Date:  1978-08       Impact factor: 3.791

Review 6.  Interleukins in immunologic and allergic diseases.

Authors:  H G Herrod
Journal:  Ann Allergy       Date:  1989-10

7.  The released interleukin 2 receptor binds interleukin 2 efficiently.

Authors:  L A Rubin; G Jay; D L Nelson
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

8.  Interleukin 2 receptor expression and interleukin 2 production in exponentially growing T cells: major differences between in vivo and in vitro proliferating T lymphocytes.

Authors:  B Rocha; M P Lembezat; A Freitas; A Bandeira
Journal:  Eur J Immunol       Date:  1989-06       Impact factor: 5.532

9.  Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

Authors:  H S Auerbach; M Williams; J A Kirkpatrick; H R Colten
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

10.  Activation of natural killer cells via the p75 interleukin 2 receptor.

Authors:  J H Phillips; T Takeshita; K Sugamura; L L Lanier
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Role of corticosteroids in cystic fibrosis lung disease.

Authors:  I M Balfour-Lynn; R Dinwiddie
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

2.  Relationship between disease severity and inflammatory markers in cystic fibrosis.

Authors:  D Y Koller; M Götz; C Wojnarowski; I Eichler
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

3.  Clinical relevance of raised soluble serum interleukin-2 receptor concentrations in cystic fibrosis.

Authors:  D Y Koller; M Götz
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

4.  Corticosteroid treatment in cystic fibrosis.

Authors:  J F Price; P Greally
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

5.  Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes.

Authors:  R B Moss; Y P Hsu; L Olds
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

Review 6.  Probiotic supplementation in children with cystic fibrosis-a systematic review.

Authors:  Anitha Ananthan; Haribalakrishna Balasubramanian; Shripada Rao; Sanjay Patole
Journal:  Eur J Pediatr       Date:  2016-08-30       Impact factor: 3.183

7.  Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis.

Authors:  P Greally; M J Hussain; D Vergani; J F Price
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

8.  Pseudomonas aeruginosa exoenzyme S is a mitogen but not a superantigen for human T lymphocytes.

Authors:  T F Bruno; D E Buser; R M Syme; D E Woods; C H Mody
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

9.  Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone.

Authors:  P Greally; M J Hussain; D Vergani; J F Price
Journal:  Arch Dis Child       Date:  1994-07       Impact factor: 3.791

10.  Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.

Authors:  Veerle Reynders; Stefan Loitsch; Constanze Steinhauer; Thomas Wagner; Dieter Steinhilber; Joachim Bargon
Journal:  Respir Res       Date:  2006-07-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.